Investments in new technologies will enable the development of new substances and products in currently unavailable niches. The EBRD loan will also be used to implement the “Go Green” modernization program aimed at minimizing the environmental and climate impact of the company’s operations.
The European Bank for Reconstruction and Development (EBRD) will grant Polpharma a loan of PLN 200 million for general and corporate purposes, including its own research and development activities, green investments and ESG strategy, the bank said.
As part of the ESG strategy, Polpharma also intends to implement a number of gender-oriented measures, including the first formal policy of diversity and social inclusion.
Polpharma is one of the leading manufacturers of generic drugs in Central and Eastern Europe, offering modern drugs, substances and innovative solutions. The company has production plants and research and development centers in Poland and Kazakhstan.